53 related articles for article (PubMed ID: 22990016)
1. Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.
Taylor SJ; Dagger SA; Thien CB; Wikstrom ME; Langdon WY
Blood; 2012 Nov; 120(19):4049-57. PubMed ID: 22990016
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN.
Montalban-Bravo G; Jabbour E; Chien K; Hammond D; Short N; Ravandi F; Konopleva M; Borthakur G; Daver N; Kanagal-Shammana R; Loghavi S; Qiao W; Huang X; Schneider H; Meyer M; Kantarjian H; Garcia-Manero G
Leuk Res; 2024 Jul; 142():107518. PubMed ID: 38744144
[TBL] [Abstract][Full Text] [Related]
3. Flt3 signaling regulates the proliferation, survival, and maintenance of multipotent hematopoietic progenitors that generate B cell precursors.
Dolence JJ; Gwin KA; Shapiro MB; Medina KL
Exp Hematol; 2014 May; 42(5):380-393.e3. PubMed ID: 24444745
[TBL] [Abstract][Full Text] [Related]
4. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders.
Naramura M; Nadeau S; Mohapatra B; Ahmad G; Mukhopadhyay C; Sattler M; Raja SM; Natarajan A; Band V; Band H
Oncotarget; 2011 Mar; 2(3):245-50. PubMed ID: 21422499
[TBL] [Abstract][Full Text] [Related]
5. Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
Taylor SJ; Thien CB; Dagger SA; Duyvestyn JM; Grove CS; Lee BH; Gilliland DG; Langdon WY
Exp Hematol; 2015 Mar; 43(3):191-206.e1. PubMed ID: 25534201
[TBL] [Abstract][Full Text] [Related]
6. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.
Lee HK; Kim HW; Lee IY; Lee J; Lee J; Jung DS; Lee SY; Park SH; Hwang H; Choi JS; Kim JH; Kim SW; Kim JK; Cools J; Koh JS; Song HJ
Blood; 2014 Apr; 123(14):2209-19. PubMed ID: 24532805
[TBL] [Abstract][Full Text] [Related]
7. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
[TBL] [Abstract][Full Text] [Related]
8. Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
Wolleschak D; Mack TS; Perner F; Frey S; Schnöder TM; Wagner MC; Höding C; Pils MC; Parkner A; Kliche S; Schraven B; Hebel K; Brunner-Weinzierl M; Ranjan S; Isermann B; Lipka DB; Fischer T; Heidel FH
Haematologica; 2014 Jun; 99(6):e90-3. PubMed ID: 24633870
[No Abstract] [Full Text] [Related]
9. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8
Powell RM; Peeters MJW; Rahbech A; Aehnlich P; Seremet T; Thor Straten P
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835225
[TBL] [Abstract][Full Text] [Related]
11. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
Kontandreopoulou CN; Diamantopoulos PT; Tiblalexi D; Giannakopoulou N; Viniou NA
Blood Adv; 2021 Nov; 5(22):4794-4805. PubMed ID: 34529761
[TBL] [Abstract][Full Text] [Related]
12. CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Belizaire R; Koochaki SHJ; Udeshi ND; Vedder A; Sun L; Svinkina T; Hartigan C; McConkey M; Kovalcik V; Bizuayehu A; Stanclift C; Schenone M; Carr SA; Padron E; Ebert BL
Blood; 2021 Apr; 137(16):2209-2220. PubMed ID: 33512474
[TBL] [Abstract][Full Text] [Related]
13. Potential targeting of FLT3 acute myeloid leukemia.
Ambinder AJ; Levis M
Haematologica; 2021 Mar; 106(3):671-681. PubMed ID: 32703795
[TBL] [Abstract][Full Text] [Related]
14. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Toure AA; Buhrlage S; Liu X; Wang J; Gray N; Stone R; Adamia S; Winer E; Sattler M; Griffin JD
J Cell Mol Med; 2020 Feb; 24(3):2145-2156. PubMed ID: 31943762
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
[TBL] [Abstract][Full Text] [Related]
16. Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy.
Taylor SJ; Langdon WY
Mol Cell Oncol; 2017; 4(6):e1378156. PubMed ID: 29209657
[TBL] [Abstract][Full Text] [Related]
17. Sleeping through the storm: Preventing myelosuppression with quizartinib.
Taylor SJ; Langdon WY
Oncotarget; 2017 Oct; 8(51):88255-88256. PubMed ID: 29179431
[No Abstract] [Full Text] [Related]
18. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors.
McIver AL; Zhang W; Liu Q; Jiang X; Stashko MA; Nichols J; Miley MJ; Norris-Drouin J; Machius M; DeRyckere D; Wood E; Graham DK; Earp HS; Kireev D; Frye SV; Wang X
ChemMedChem; 2017 Feb; 12(3):207-213. PubMed ID: 28032464
[TBL] [Abstract][Full Text] [Related]
20. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.
DeRyckere D; Lee-Sherick AB; Huey MG; Hill AA; Tyner JW; Jacobsen KM; Page LS; Kirkpatrick GG; Eryildiz F; Montgomery SA; Zhang W; Wang X; Frye SV; Earp HS; Graham DK
Clin Cancer Res; 2017 Mar; 23(6):1481-1492. PubMed ID: 27649555
[No Abstract] [Full Text] [Related]
[Next] [New Search]
